Fertily is a specialized treatment tracker for individuals undergoing IVF, ICSI, and FET cycles, available on iOS and Android.
The App DNA
What makes this app unique?
The app removes the cognitive friction of managing complex medical schedules and embryo inventory by centralizing disparate treatment data into a single, private timeline.
For Individuals undergoing complex fertility treatments who require a secure, organized, and private tool for medical and financial tracking.
What does it look like?
Key features
Provides read-only access to treatment timelines for partners, increasing retention through shared accountability.
Tracks embryo grades and PGT-A results, creating a specialized utility that is difficult to migrate to generic trackers.
Syncs sleep and heart rate data to position the app as a central health hub.
How much does it cost?
The app operates as a free, ad-free utility, likely serving as a founder-led project to build brand equity in the fertility space.
Velocity
Active developmentinternationalizationUX improvementsnew contentShow more...
Fertily is currently in an active development phase, shipping two distinct versions within the last 10 days. The development team is focused on both platform-specific feature parity and core functionality, including health data integration and cycle insights. This recent activity indicates a stable and productive release cycle aimed at expanding the app's utility for fertility tracking. The cadence is consistent with a product actively building out its primary feature set.
Who built it?
User Sentiment
What do users think recently?
How are ratings & reviews evolving?
Not enough recent reviews to extract reliable themes yet.
Read the full review analysisCompetition
Competitive landscape for Fertily: Treatment Tracker
How's the Health & Fitness market?
Fertily occupies a niche in the Health & Fitness category by prioritizing specialized medical utility over broad wellness tracking. The absence of a monetization layer distinguishes it from category incumbents that typically gate advanced tracking features behind subscription tiers.
Read the market outlookThe rivals identified
Unlock the deeper market read.
Access the full report for freeThe Analyst's Read
Key takeaways for Fertily: Treatment Tracker
Where is it heading?
The fertility-tracking market is consolidating around specialized tools that offer more than just cycle logging. Fertily's focus on medical-grade inventory management positions it well to capture users who find generic trackers insufficient, provided the team can establish a sustainable growth model.
- Active release cadence with two updates in the last 10 days signals strong development momentum and responsiveness to user needs.
- The recent expansion into multi-language support indicates a push for international accessibility, which will broaden the potential user base by Q4.
The SWOT
- Partner Mode drives shared accountability and retention
- Embryo inventory management creates high switching costs
- Ad-free, free-to-use model lowers adoption friction
- Clinical data export features could streamline patient-clinic communication
- Community-based support forums could increase daily active usage
- Partnerships with fertility clinics could accelerate user acquisition
Next best moves
Ship clinical data export feature because it addresses the primary information-sharing friction between patients and clinics → increase utility and retention
+ 1 more prioritized moveThe counter-intuitive read
Fertily's ad-free, free-to-use model is not a weakness but a strategic moat…
Read the full takeSince the last report: Fertily has shifted its strategic focus toward clinical utility and specialized medical tracking, moving away from a purely acquisition-based narrative to one centered on high switching costs and medical-grade data management.
Bottom line
Fertily's specialized utility for embryo and cycle tracking provides a clear value proposition for patients, but the lack of a sustainable monetization model risks long-term development velocity.
Unlock 3 critical frictions, 3 market threats, 1 more prioritized move and the analyst’s take.
Access the full report for freeSources
Report last updated